Kornimate/medical-research-clean huggingface dataset:
e-gab: electronic geriatric assessment bundle: development of an arabic self-administered android cga application

Conditions: Health Services for the Aged; Frailty; Cognitive Impairment; Depression; Disability Physical; Urinary Incontinence; Malnutrition

Summary: the aim of this study is to design and assess the accuracy of administering the electronic geriatric assessment bundle (e-gab) compared to geriatrician performed comprehensive geriatric assessment (cga) in a group of egyptian elderly. the development of an arabic software platform for cga can improve the clinical practice by providing a valid user friendly tool to collect and analyze data for geriatric patients attending non- geriatric health care service.

modern geriatric care is based primarily on the concept of multidisciplinary approach of elderly care. this could be achieved by integrating cga in different disciplines dealing with the older patient. cga is different from that of the standard medical evaluation; it is a systematic evaluation of frail older adults. it uses combinations of validated geriatric tools to formulate an inventory of health problems, and develop an individualized geriatric intervention plan. the software platform for cga has been widely used in western countries; however, tools that can fit patients with different backgrounds should be implemented.. from the initial pool of 3 potential subtests, four experienced geriatricians developed a bundle of 15 subtests, to evaluate cognition, mood, vision, hearing, urinary continence, nutrition, functional capacity, fall risk and balance impairment, frailty, polypharmacy, sleep, pain, home safety, and social problems. moreover, a rapid survey of medical and surgical conditions was obtained. initial evaluation of these subsets compared to the reference standard cga was done. each patient completed the bundle then underwent cga by an experienced geriatrician blinded to the result of e-gab

Eligibility criteria:
inclusion criteria: * 60 years or above * community dwelling * can read and write * can use the android application exclusion criteria: * any patient refused to participate

Keywords: comprehensive geriatric assessment telemedicine multidisciplinary approach of elderly care electronic geriatric assessment bundle
evaluation of the success of prophylactic enteral nutrition in therapeutic intensification with autograft of autologous hematopoietic cells in hematology

Conditions: Lymphoma; Myeloma

Summary: when the digestive tract is functional, learned societies recommend the use of a nutritional support by enteral feeding. indeed, it has many advantages (maintenance of gut trophicity, reduction of the risk of infection by reducing the incidence of bacterial translocations,...). it has been used for about fifteen years in hematology departments and offers promising results in the context of allogeneic transplantation with prospective trials in progress (nepha study). however, its tolerance has not been studied during autologous transplantation. this study aims to assess the success of enteral nutrition in this setting.

in the literature, there are many studies on the nutritional support to be used during allografts, that highlight the superiority of enteral nutrition over parenteral nutrition in terms of reducing co-morbidities. enteral nutrition is the nutritional support recommended by learned societies for therapeutic intensification with autograft of autologous hematopoietic cells in hematology. nevertheless, enteral nutrition presents difficulties in its implementation and failures (refusal of patients, probes vomiting, neutropenic colitis, etc.), requiring the use of parenteral nutrition in case of failure. in this context, the study proposes to assess the success and effectiveness of enteral nutrition.

Eligibility criteria:
inclusion criteria: * patient with lymphoma or myeloma * patient admitted for therapeutic intensification with autologous hematopoietic cells who are eligible for nutritional support by enteral nutrition * free, informed and written consent signed by the patient exclusion criteria: * refusal of the enteral nutrition * all patients with absolute or enteral nutrition contraindications: * digestive fistula * intestinal obstruction * intestinal ischemia * active digestive bleeding * digestive malabsorption (short hail syndrome, bariatric surgery, gastrectomy) * trauma to the base of the skull or significant deviation of the nasal septum not allowing the insertion of an naso gastric probe. * esophagitis or barrett's esophagus * persistent gastro-duodenal dysfunction (gastroparesis) * patients admitted for autograft for the treatment of conditions other than lymphoma or myeloma (e. g. solid tumours or leukaemia)

Keywords: autologous stem cell transplantation enteral feeding myeloma lymphoma
cardiac ct's role in asymptomatic patients with diabetes and metabolic syndrome

Conditions: Diabetes; Metabolic Syndrome

Summary: this study looked at the role of cardiac ct in improving risk factor control in those with diabetes.

this study examined whether doing a cardiac screening test, the cardiac ct, would result in patients paying more attention to controlling their risk factors.

Eligibility criteria:
inclusion criteria: * age \> 18 * diabetes * metabolic syndrome exclusion criteria: * symptoms of heart disease * heart disease * renal disease
initiating early control of migraine pain and associated symptoms

Conditions: Migraine

Summary: axs-07 is an oral, investigational medicine consisting of moseic meloxicam and rizatriptan, which is being developed for the acute treatment of migraine with or without aura in adults. axs-07 tablets are formulated to provide an enhanced rate of absorption of meloxicam. this study is designed to evaluate the efficacy and safety of axs-07 compared to placebo. this is a randomized, double-blind, single-dose, placebo-controlled trial. subjects who successfully complete the screening period and continue to meet all entry criteria will be randomly assigned to take one dose of either axs-07 or placebo upon the earliest onset of migraine pain.


Eligibility criteria:
key inclusion criteria: • has an established diagnosis of migraine with or without aura. key exclusion criteria: * has previously received any investigational drug or device or investigational therapy within 30 days before screening. * pregnant, breastfeeding, or planning to become pregnant or breastfeed during the study.

Keywords: migraine axs-07 meloxicam rizatriptan
hyfosy versus hsg as a diagnostic technique for tubal patency.

Conditions: Tubal Patency; Sterility

Summary: observational, single-center, prospective case-control study, in which each patient is his own control. it focuses on the study of tubal patency and establishing the agreement of results between hyfosy and hsg.

observational, single-center, case-control study in which tubal pathology is studied in the context of a basic sterility study. the main objective of this study is to demonstrate the concordance of this new diagnostic test (hyfosy) with hsg, which is the common technique to visualize tubal patency. once demonstrated concordance, we also want to carry out a cost-effectiveness study and demonstrate through different scales the greater ease of the test, less time to perform and less pain for the patient. it is a study in which the patients are women between 18-39 years old, undergoing study for primary sterility, with a bmi \ 0.6 (good ovarian reserve).

Eligibility criteria:
inclusion criteria: * women between 18-39 years, under study for primary sterility, with bmi \ 0.6 (good ovarian reserve), subsidiaries of conjugal or donor ia, according to the 2019 sas reproduction guide. exclusion criteria: * women \ 39 years old, bmi\> 30, secondary sterility, previous tubal sterilization, that is, the art exclusion criteria according to the 2019 sas reproduction guide.
evaluation of mucogyne® ovule in vulvovaginal dryness management in women treated by brachytherapy and/or radiotherapy for endometrial or cervical cancer.

Conditions: Vaginal Disease

Summary: randomized, open-label, national (france), multicenter, prospective clinical study, to evaluate the superiority of mucogyne® ovules over the control group on vaginal health (including hydration) in women treated by brachytherapy and/or radiotherapy for endometrial or cervical cancer.


Eligibility criteria:
inclusion criteria: * woman over 18 * hysterectomized patient with endometrial cancer (stage i, stage ii and histological type i, without chemotherapy, with brachytherapy and/or radiotherapy) or patient with cervical cancer (stage ia2 and ib1 with emboli or positive lymphadenopathy and ib2 stages with or without chemotherapy, with brachytherapy and / or radiotherapy) * only for patients with cervical cancer, premenopausal and non-hysterectomized: patient on contraception at least one month before v0 and throughout the study * only for patients with cervical cancer: complete remission * patient capable of receiving and understanding information related to the study, giving informed written consent, and easily completing a quality of life questionnaire * patient affiliated to the french social security system exclusion criteria: * patient with clinically observed vulvovaginal infections * patient with endometrial cancer treated with chemotherapy * patient already participating in another study * patient under legal protection, or under guardianship or curatorship * only for patients with cervical cancer: local treatment with estrogen * only for patients with cervical cancer, premenopausal and non-hysterectomized: pregnancy (pregnancy test to be performed at v0)

Keywords: vaginal dryness
analysis of anti-inflammatory and antioxidant pathways in lung diseases by haem oxygenase-1 (ho-1) in induced sputum and carbon monoxide (co) in exhaled air

Conditions: Lung Diseases

Summary: this work will focus on the anti-inflammatory and antioxidant pathways in lung diseases by measuring ho-1 in induced sputum and co in exhaled air in cases of four respiratory diseases, asthma, chronic obstructive pulmonary disease (copd), occupational lung diseases (old) and interstitial lung disease (ild).


Eligibility criteria:
inclusion criteria: * male and female * ages \>/= 18 years * diagnosed with one or more lung diseases * referred for sputum induction to the pulmonary laboratory in the tel-aviv sourasky medical center

Keywords: mucus-stimulated (induced sputum) lung disease (asthma, copd, ild and old) ho-1 (heme oxigenase-1) oxidative stress co (carbon monoxide) the oxidative stress in lung diseases
advance® vs argus® sling procedure in male with post prostatectomy stress urinary incontinence

Conditions: Stress Urinary Incontinence

Summary: the study is designed to assess efficacy and subject satisfaction of two sling devices: advance and argus, in male patients with stress urinary incontinence after prostatectomy.


Eligibility criteria:
inclusion criteria: * the subject is male * the subject is at least 18 years of age * the subject has an estimated life expectancy of more than 5 years * the subject has confirmed stress urinary incontinence (sui) through medical history, urodynamics, and/or physical exam for at least 6 months * the subject has intrinsic sphincter deficiency due to one of the following: post-turp, simple open prostatectomy, radical prostatectomy completed at least 6 months prior to implantation date * positive cough stress test (cst): * positive 24-hours pad test (pt): a positive pt is confirmed with leakage of \>8.o g/24h and \< 400 g * the subject has completed urodynamics, uroflow, post-void residual, and cystoscopy as per the protocol within 6 months prior to implant * the subject is able and willing to complete all follow-up visits and procedures indicated in this protocol * the subject has been informed of the nature of the study and agrees to its provisions and has provided written informed consent as approved by the local ethics commit-tee of the respective site exclusion criteria: * subjects who meet any of the following criteria are excluded from entry into the study * the subject is unable or unwilling to sign the informed consent form (icf) and/or comply with all follow-up requirements according to the study protocol * the subject has an active urogenital infection or active skin infection in region of surgery * the subject has serious bleeding disorders * the subject has incontinence due to neurogenic causes defined as multiple sclerosis, spinal cord/brain injury, cva, detrusor-external sphincter dyssynergia, parkinson's disease, or similar conditions * the subject had a previous implant to treat stress urinary incontinence * the subject has undergone radiation, cryosurgery, or brachy therapy to treat prostate or other pelvic cancer within 6 months * the subject is likely to undergo radiation therapy within the next 6 months * the subject has active urethral or bladder neck stricture disease, requiring continued treatment * the subject has urge predominant incontinence * the subject has an atonic bladder or a postvoid residual (pvr) ≥150ml * the subject has a condition or disorder likely to require future transurethral procedure * the subject is enrolled in a concurrent clinical trial of any treatment (drug or device) that could affect continence function without the sponsors'approval * subjects who in the opinion of the investigator are unable and/or unlikely to to comprehend the nature, scope and possible consequences of the study and to follow the study procedures and instructions and complete all study related measurements.

Keywords: stress urinary incontinence post prostatectomy
effectiveness of combined neural mobilization with manual myofascial release for sciatic pain relief

Conditions: Sciatica

Summary: this study will address to evaluate and compare both neural mobilization and manual myofascial release of piriformis and lumbar muscles in sciatic pain with the aim of evaluating and identifying the most effective intervention for managing this specific condition, and provide valuable insights into the effectiveness, mechanisms, and practical considerations associated with these interventions, ultimately contributing to evidence based and patient centered care.

mfr is a hands-on technique targeting fascial restrictions that may contribute to pain and reduced mobility. barnes proposed that releasing fascial adhesions can improve circulation, reduce nerve compression, and enhance tissue flexibility. in a study by ajimsha et al. , mfr was found to significantly reduce pain and improve physical function in patients with nonspecific low back pain. there is a lack of comparative research assessing the relative efficacy of neural mobilization andmfr in sciatic pain management. while both techniques are rooted in distinct mechanisms neural desensitization versus fascial release they may have overlapping benefits in improving mobility and reducing pain. this study addresses this research gap by directly comparing the two approaches in individuals with sciatic pain.

Eligibility criteria:
inclusion criteria: 1. clinically diagnosed unilateral sciatic pain for \>3 months. 2. positive straight leg raise (slr). exclusion criteria: - participants fall in this category would be excluded of the study. 1. recent spinal surgery or trauma. 2. neurological deficits or systemic conditions affecting the nervous system. 3. any other red flags

Keywords: neural mobilization myofascial release sciatic pain
a pre-post intervention study evaluating home-based management of patients with copd or cap

Conditions: Chronic Obstructive Pulmonary Disease; Community-acquired Pneumonia

Summary: risk of rehospitalization within 30 days of discharge is higher than 20% in patients with chronic obstructive pulmonary disease (copd) and up to 20% for patients with community acquired pneumonia (cap). this pre-post intervention study aims to quantify the impact of continuous remote patient monitoring (rpm) on rates of hospital readmission for patients presenting with cap or exacerbation of copd and compare the intervention group to historical controls that did not have access to the intervention. we hypothesize that an intervention combining remote patient monitoring with the remote clinical services and escalation pathways available at ssh (including the mobile integrated health (mih) program) will reduce hospital readmission within the 30 days following hospital discharge compared to standard of care in this population.


Eligibility criteria:
inclusion criteria: * 21 years or older * confirmed diagnosis of moderate-severe copd or community acquired pneumonia * attendance at south shore hospital with an exacerbation of copd / cap * fit for discharge to home exclusion criteria: * suspicion of covid-19 or confirmed covid-19 positive * life-threatening exacerbation requiring invasive ventilation or prolonged stay in critical care (\> 24 hours) * unable/unwilling to use current health * bilateral axillary lymph node dissection * persistent atrial fibrillation * heavy tattooing on upper arms * discharged to skilled nursing facility * no access to home or mobile telephone

Keywords: wearable current health platform 30 day readmission
mp-mri in the diagnosis of liver fibrosis after liver transplantation

Conditions: Liver Fibrosis After Liver Transplantation; Multiparameter Magnetic Resonance Imaging

Summary: it is an open label observation clinical trial, all participants are liver transplant patients. the investigators deem to make a better criteria for assessing liver fibrosis after liver transplantation. the point of the clinical trial is to evaluate the efficacy of multiparameter mri in the diagnosis of liver fibrosis after liver transplantation.

we collected patients aged 18 to 85 who had undergone liver transplantation. at the same time, all patients underwent liver biopsy or ultrasonic transient elastography after mri. people who were allergic to gadolinium contrast agent, serious cardiopulmonary disease and contraindications to mri were excluded.

Eligibility criteria:
inclusion criteria: * subjects aged 18 -85 years * patients after liver transplantation * patients who are going to undergo liver biopsy or ultrasonic transient elastography * patients voluntarily joined the study and signed informed consent exclusion criteria: * patients with tumor * patients who are allergic to gadolinium contrast agent * patients with contraindications to magnetic resonance imaging * patients with severe heart and lung diseases * patients who are not suitable for this study according to the researcher's judgment.
the inselspital surgical cohort study

Conditions: Surgical Site Infection

Summary: personalizing surgical care is of enormous clinical relevance, when considering the number of patients undergoing surgery in switzerland every year. currently, personalization is based on underlying or coexisting disease or alterations of laboratory values, but there is no accepted biological test available that may predict success or failure of surgery. surgical site infections are the most common form of hospital-acquired infections. while the relevance of bacteria, antibiotics and intensive care support is well accepted, the impact of the individual host response remains poorly understood. the investigators hypothesize that postoperative alterations of the metabolome allow identification of predictors of surgical complications in general, and surgical site infections in particular.

the investigators will conduct a prospective cohort study aiming to identify the metabolic and genetic signature that is associated with surgical site infections. secondary aims and outcomes include the influence of metabolome on response to anesthetic drugs and acute and chronic pain, surgery- and anesthesia-factors related to short- and long-term oncological outcome, metabolic response effect on infectious complications and rejection after transplantation, bacteria-specific immune responses to major surgery after 2-4 weeks after surgery, metabolomics and macrobiotic markers for postoperative ileus or anastomotic leakage, and the effect of the presence of multidrug resistant bacteria on surgical outcome. all patients undergoing surgery in the investigators' clinic and who gave informed consent will be included. a blood sample will be taken before surgery, on the first postoperative day and after 3-8 weeks. a urine sample will be taken after surgery and after 3-8 weeks. sink and rectal swabs will be acquired before surgery. the samples will be stored in a biobank. additionally, all data routinely captured during the treatment of the patient from the different data collection systems in use in the investigators' hospital will be coded and centralized in a single, cohort database

Eligibility criteria:
inclusion criteria: * patients undergoing surgery at the department of visceral surgery and medicine, inselspital, university hospital bern * who gave general consent * study-specific written informed consent exclusion criteria: * none

Keywords: cohort visceral surgery biobank
essential-"the studies of oral enoximone therapy in advanced heart failure"

Conditions: Heart Failure, Congestive

Summary: to determine if low-dose enoximone therapy is an effective treatment for advanced chronic heart failure.

the study is a randomized, double-blind, multicenter, parallel group, placebo-controlled trial of oral enoximone in approximately 700 subjects with advanced chronic heart failure of either ischemic or nonischemic etiology receiving optimal conventional heart failure therapy. eligible subjects will be randomized in a 1:1 ratio to receive either enoximone or placebo at the randomization visit. the initial dose of study drug will be 25 mg t.i.d.(3xday) and will be administered immediately after randomization. subjects who tolerate this initial dose will be continued on 25 mg t.i.d. for at least two weeks. after two weeks, eligible subjects will be titrated to 50 mg t.i.d. for the duration of the study.

Eligibility criteria:
in order to be considered eligible subjects, the following entry criteria must be met: * at least 18 years of age * ischemic or nonischemic cardiomyopathy * nyha class iii or iv * one hospitalization, or two outpatient visits, for the treatment of worsening heart failure within 12 months requiring the administration of i.v. heart failure therapy * lvedd \>3.2 cm/m2 or \>=6.0 cm * lvef of less than or equal to 30% * concomitant treatment with optimal conventional heart failure therapy exclusion criteria subjects who meet any one of the following criteria will be deemed ineligible for participation in the study: subjects on the following concomitant medications: * calcium antagonists other than amlodipine or felodipine * flecainide, encainide, propafenone, dofetilide or disopyramide * subjects receiving i.v. positive inotropic agents within seven days of the screening visit or randomization visit * subjects receiving a human b-type natriuretic peptide, including nesiritide, within seven days of the screening visit or randomization visit * subjects receiving oral or i.v. phosphodiesterase iii inhibitors (pdei iii), including levosimendan and cilostazol, within seven days of the screening visit or randomization visit * subjects with active hepatic (screening serum total bilirubin \>= 3.0 mg/dl (\>=51.3 umol/l), renal (screening serum creatinine \>= 2.0 mg/dl (=178.8 umol/l)), hematologic, gastrointestinal, immunologic, endocrine, metabolic, or central nervous system disease * subjects with a serum potassium \ 5.5 meq/l (\ 5.5 mmol/l) at randomization visit * subjects with a magnesium level of \<1.0 meq/l (\<0.5 mmol/l) at randomization visit (visit 0) * subjects with a serum digoxin of \>1.2 ng/ml (\>1.5 nmol/l) or a serum digitoxin of \>20 ng/ml (\>26.2 nmol/l) at the randomization visit are excluded. a target serum digoxin level of \<=1.0 ng/ml (\<=1.3 nmol/l) is recommended

Keywords: chf heart failure congestive enoximone phosphodiesterase inhibitor